Structure Therapeutics
NASDAQ: GPCR
Developing oral therapies for chronic metabolic and cardiovascular diseases.
Sector
Life SciencesCategory
TherapeuticsLocations
Shanghai, ChinaSan Diego, CA
Initial Investment
2019
Developing oral therapies for chronic metabolic and cardiovascular diseases.
Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.
“F-Prime shares our commitment to developing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies and provide better treatment options for patients everywhere.
”
Raymond Stevens, Ph.D., Founder & CEO
